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ABSTRAK
Latar belakang: Amikasin merupakan salah satu pilihan antibiotik untuk tatalaksana sepsis dan syok septik. 
Kondisi sepsis dapat mempengaruhi farmakokinetik amikasin yang juga dapat berefek pada farmakodinamiknya. 
Saat ini belum pernah dilakukan penelitian untuk mengevaluasi kadar puncak (Cmax) amikasin dengan dosis 
standar pada pasien sepsis dewasa di Indonesia. Tujuan penelitian ini adalah untuk mengetahui ketercapaian 
kadar amikasin optimal pada pasien sepsis dengan dosis standar. Metode: semua pasien sepsis di ICU RSCM 
periode Mei-September 2015 yang mendapat amikasin dosis 1 g/hari IV diikutkan dalam penelitian. Data hasil 
kultur mikrobiologi dan minimum inhibitory concentration (MIC) didapatkan dari pemeriksaan mikrobiologi. 
Dilakukan pengukuran Cmax amikasin dan penghitungan Cmax/MIC. Kadar optimal amikasin dinyatakan 
tercapai bila Cmax/MIC >8. Hasil: rerata Cmax amikasin adalah 86,4 (kisaran 43,5-238) µg/mL, dengan 
87% pasien memiliki Cmax >64 µg/mL. Data MIC didapatkan dari 7 dari 23 pasien. Bakteri yang banyak 
ditemukan dari hasil kultur pasien sepsis di ICU RSCM ialah K. pneumonia, A. baumanii, P. aeruginosadan 
E. coli. Rentang nilai MIC untuk patogen tersebut berturut-turut yaitu 0,75 - >256 µg/mL, 0,75 - >256 µg/mL, 
1,5 - >256 µg/mL dan 0,75 - 16) µg/mL. Sebanyak 4 dari 7 pasien mencapai kadar amikasin yang optimal. 
Kesimpulan: Cmax amikasin yang dicapai dengan dosis 1g/hari sangat bervariasi. Hanya sebagian pasien 
mencapai kadar amikasin optimal meskipun kadar puncak yang dicapai cukup tinggi. Pengukuran kadar puncak 
dan MIC bakteri sangat penting dalam mencapai terapi yang optimal.
Kata kunci: Amikasin, Cmax, intensive care unit (ICU), minimum inhibitory concentration (MIC), sepsis.
ABSTRACT
Background: Amikacin is one of the antibiotics of choice for sepsis and septic shock. Pharmacokinetic 
of amikacin can be influenced by septic condition with subsequent effect on its pharmacodynamic. At Cipto 
Mangunkusumo Hospital (RSCM), Jakarta, adult patients in the ICU were given standard amikacin dose of 1 
g/day, however the achievement of optimal plasma level had never been evaluated. This study aimed to evaluate 
whether the optimal plasma level of amikacin was achieved with the use of standard dose in septic conditions. 
Methods: all septic patients admitted to the intensive care unit of a national tertiary hospital receiving standard 
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dose of 1g/day IV amikacin during May-September 2015 were included in this study. Information of minimum 
inhibitory concentration MIC was obtained from microbial culture. Cmax of amikacin was measured 30 minutes 
after administration and optimal level was calculated. Optimal amikacin level was considered achieved when 
Cmax/MIC ratio >8. Results: average Cmax achieved for all patients was 86.4 (43.5-238) µg/mL with 87% 
patients had Cmax of >64 µg/mL.MIC data were available for 7 of 23 patients. MICs for identified pathogens 
were 0.75 - >256 µg/mL (K. pneumonia), 0.75 - >256 µg/mL(A. baumanii), 1.5 - >256 µg/mL (P. aeruginosa)
and 0.75 – 16 µg/mL(E. coli). Four out of seven patients achieved optimal amikacin level. Conclusion: despite 
high Cmax, only half of the patients achieved optimal amikacin level with highly variable Cmax. This study 
suggests that measurement of Cmax and MIC are important to optimize septic patients management.
Keywords: Amikacin, Cmax, intensive care unit (ICU), minimum inhibitory concentration (MIC), sepsis.
INTRODUCTION
Septic shock and severe sepsis are among 
the causes of high mortality in Intensive Care 
Unit (ICU) patients.1,2 The incidence of sepsis 
and severe sepsis varies all around the world, 
ranging from 20 to 80%.2,3 Mortality rate for 
sepsis is 20-50% worldwide, and 44.5% in Asia. 
Surviving Sepsis Campaign have recommended 
resuscitation in 6 hours to decrease mortality; 
including blood culture and antibiotic therapy.3,4
A study involving 13.796 subjects in 75 
countries showed that pathogens causing infections 
in ICU were mostly gram-negative organisms 
(62%).5 Amikacin is an aminoglycoside antibiotic 
that kills Gram-negative bacteria, including in 
severe infection.6,7 Amikacin is effective in killing 
88% bacteria resistant to gentamicin.8 Resistance 
to amikasin is lower than gentamicin, because 
some enzyme produced by bacteria could not 
inactivate amikacin.6,9
The killing potency of amikacin depends 
on its peak concentration (Cmax) in plasma.9 
Cmax/MIC ratio is one of pharmacokinetic-
pharmacodynamic (PK-PD) parameter used 
for an antibiotic with concentration dependent 
killing activity and Cmax/MIC ratio above 8 is 
required for it to be clinically effective.10 MIC 
of bacteria varies, so therapy should be based on 
bacteria endemic pattern in each clinical setting. 
In the ICU, where Enterobacteriaceae and 
Pseudomonas aeruginosa were the most common 
pathogen, the clinical breakpoint of MIC is 
8 µg/mL.11,12 Clinical breakpoints are used in 
the clinical laboratory to advise the therapy of 
patients, by classifing the microorganism as 
clinically susceptible, intermediate or resistant 
based on MIC value.12 Thus, Cmax should be at 
least 64 µg/mL to reach the optimum therapy.11 
Pharmacokinetic of amikacin can be influenced 
by septic condition due to the increase of volume 
distribution and clearance alteration.13,14 Study 
by Duszynska et al.15 on 63 ICU patients showed 
that 36% patients needed higher doses to reach 
optimal levels of amikacin, while in 38% patients 
the dose should be decreased.
Amikacin is one of the drugs of choice for 
infectious disease at intensive care unit of Cipto 
Mangunkusumo Hospital (RSCM), Jakarta, 
Indonesia. For practical reasons, this drug is 
administered 1g once daily intravenously for 
every patient, irrespective of body weight 
(BW). There is no data about achievement of 
optimal blood levels related to MIC with this 
regimen dosing. The aim of this study was to 
evaluate the peak levels (Cmax) and Cmax/MIC 
ratio of amikacinin septic patients following 
administration of 1 g amikiacin IV in ICU RSCM.
METHODS
This cross sectional study was conducted 
from May to September 2015 in the internal 
care unit (ICU) of RSCM Jakarta, Indonesia. 
The subjects were adult patients with sepsis 
in the ICU. Inclusion criteria were patients 
aged 18-65 years old, and receiving amikacin 
as antibiotic for sepsis. Patients with creatinin 
clearance below 60 mL/minutes were excluded. 
The study protocol was approved by the Ethics 
Committee of Faculty of Medicine, Universitas 
Indonesia – Cipto Mangunkusumo Hospital 
(FMUI-RSCM). Informed consents were taken 
from closest relatives in case where patients were 
unable to communicate.
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Pharmacodynamic parameters of amikacin 
can be determined from Cmax/MIC ratio and 
AUC/MIC ratio. In this study, Cmax/MIC ratio 
was used to determine optimal amikacin levels.
Cmax/MIC ratio of 8 or more was considered as 
the optimal amikacin levels. The susceptibility 
rate was counted based on Clinical and Laboratory 
Standards Institute (CLSI), which susceptibility 
for Enterobacteriaciae (Klebsiellapneumoniae, 
Escherichiacoli), P. aeruginosa and Acinetobacter 
spp. were 16 µg/mL or less.15
The proportion of patients who reached the 
therapeutic levels of amikacin was determined. 
Most of the common pathogen in ICU had the 
clinical breakpoint of MIC of 8 µg/mL.11,12 So, 
amikasin therapeutic levels is reached when 
Cmax >64mg/dL. Amikacin dose was analyzed 
by normalization of dose given (1 g) with 
patient’s body weight to fulfill the recommended 
amikacin septic dose of 25 mg/kgBW. It was 
defined as underdose if patients received 
amikacin below 25 mg/kgBW.
All patients included in the study received 
1 g amikacin by slow infusion for 30 minutes. 
Blood samples were taken at 30 minutes after 
infusion. Blood was collected in a 5-mL tube 
with EDTA. The samples were centrifuged for 
10 minutes and the serum was stored at –20oC 
until analysed further. To quantify amikacin 
serum levels Liquid Chromatography Tandem 
Mass Spectrometry (LC-MSMS) was used in 
Laboratorium Kesehatan Daerah Provinsi DKI 
Jakarta.
The pathogens that infected the patients 
whenever possible and pooled samples from 
ICU patients in RSCM during study period were 
determined by culture, as well as the MIC. The 
method to determined MIC was E-test with MIC 
evaluator from Liofilchem®. Optimal amikacin 
levels was calculated from Cmax and MIC. 
Bacterial culture and MIC tests were done in 
Clinical Microbiology Labotarorium of FMUI-
RSCM. Data were analyzed by using SPSS 
version 20.0.
RESULTS
Twenty four patients were enrolled during 
the study period. One patient died before blood 
sample was taken, so only 23 patients were 
included in analysis (Tabel 1). The median 
age was 39 years old (range 18-64). Most of 
the patients had decreased renal function (i.e. 
creatinin clearance 60-90 mL/min). In about 
48% (11/23) of the samples, the focal infection 
of sepsis were lung origin, such as community 
acquired pneumonia (CAP), health care-
associated pneumonia (HCAP) and hospital-
acquired pneumonia (HAP). Mixed infection 
was defined when a patient has more than one 
source of infection. There were 2 patients with 
lung and urogenital infection and 2 patients with 
lung and wound infection).
Table 1. Characteristics of subjects at Intensive Care 
Unit, Cipto Mangunkusumo Hospital (N=23)
Variables Value
Gender, n (%)
 - Male 11 (47.8)
 - Female 12 (52.2)
Age (years), median (range) 39 (18-64)
Body Mass Index (kg/m2), mean (SD) 22.1 (5.5)
 - <18,5 (underweight), n (%) 6 (26.1)
 - 18,5 – 24,9 (normal), n (%) 12 (52.2)
 - 25 – 29,9 (overweight), n (%) 3 (13.0)
 - > 30 (obese), n (%) 2 (8.7)
Creatinin clearance, n (%)
 - 60-90 mL/min 19 (82.6)
 - >90 mL/min 4 (17.4)
Focal infection, n (%)
 - Lung 11 (48.0)
 - Wound  7 (30.0)
 - Urogenital 1 (4.0)
 - Mixed infection 4 (18.0)
Optimal Amikacin Serum Levels 
Cmax/MIC ratio was calculated from Cmax 
and MIC data. As shown in Table 2, the peak 
levels of amikacin were 86.4 (43.5-238) µg/mL, 
and the proportion of patients with peak levels 
>100 µg/mL was the largest (Figure 1).
If Cmax/MIC ratio >8 was used as the cut-
off of optimal regimen, the peak levels above 64 
μg/mL be considered optimal for pathogen with 
MIC 8 μg/mL. Twenty patients (87%) reached 
peak serum concentrations above 64 μg/mL.
Samples were collected for MIC of pathogens 
that infected patients in ICU during the study 
period. Data were collected from 7 patients 
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included in this study. Four out of those seven 
patients (57%) had optimal amikacin levels 
against pathogen causing their sepsis (Cmax/
MIC ratio >8). (Table 3)
Table 2. Peak level compared to therapeutic target (Peak >64 µg/mL) and amikacin dose received/kgBW compared to 
recommended dose for sepsis (25 mg/kgBW)
Patient No. Body weight (kg) Received dose (mg/kgBW) Peak (µg/mL)
Within 
therapeutic level Dosing category
1 40 25 96.46 Yes Appropriate
2 70 14.3 181.5 Yes Underdose
3 55 18.2 223.04 Yes Underdose
4 50 20 103.31 Yes Underdose
5 51 19.61 91.78 Yes Underdose
6 65 15.38 71.7 Yes Underdose
7 60 16.67 238.01 Yes Underdose
8 60 16.67 45.17 No Underdose
9 45 22.22 74.48 Yes Underdose
10 46 21.74 66.82 Yes Underdose
11 35 28.57 143.46 Yes Overdose
12 55 18.18 43.53 No Underdose
13 60 16.67 128.2 Yes Underdose
14 70 14.28 86.4 Yes Underdose
15 51 19.61 83.39 Yes Underdose
16 60 16.67 45.87 No Underdose
17 60 16.67 86.49 Yes Underdose
18 60 16.67 147.93 Yes Underdose
19 90 11.11 69.56 Yes Underdose
20 45.7 21.88 68.60 Yes Underdose
21 40 25 75.16 Yes Appropriate 
22 70 14.28 114.02 Yes Underdose
23 63 15.87 75.80 Yes Underdose
Median/mean 56.6 (SD12.3) 18.5 (SD 4.1) 86.4 (43.5-238)
CI 95% 51.3-61.9 16.7-20.3
Figure 1. Distribution of serum peak levels (n=23)
There were interesting finding in this study 
where three patients reached therapeutic levels 
but not optimal levels and one patient had 
optimal levels but did not reach therapeutic 
levels.
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Regimen and Peak Levels of Amikacin
All patients received amikacin 1 g once 
daily. If the dose was calculated to patient’s body 
weight, in average the patients received 18.5 
+ 4.1 mg/kgBW/day (Table 2). This dose was 
lower than the usual recommended daily dose 
(15 mg/kgBW) and higher than recommended 
dose for sepsis (25 mg/kgBW). Only 2 patients 
received amikacin with the recommended dose.
Most of the patients (17/23) received 
the dose of <25 mg/kg/day, but still reached 
therapeutic levels. Most of the patients (18/23) 
received amikacin in the range of 15-25 mg/
kgBW, whereas only 4 out of 23 received dose 
less than 15 mg/kgBW and only one received 
more than 15 mg/kgBW.  Only three patients 
received sub-therapeutic levels of amikacin 
(Table 4).
isolates were found with K. pneumoniae was the 
most frequent bacteria (44%). 
Percentage of K. pneumoniae and E. coli that 
was susceptible to amikacin (MIC <16 µg/mL) 
was quite high, however the percentage was low 
for A. baumanii and P. aeruginosa.
DISCUSSION 
Optimal concentration of amikacin is 
determined by Cmax/MIC ratio. MIC pathogen 
in ICU was 8 µg/mL.7,11,16 There where no data 
about MIC of pathogens in our ICU. Based 
on the literatures, the amikacin levels in this 
study was targeted at Cmax >64 µg/mL. Most 
(87%) patients reached Cmax of >64 µg/mL. 
This finding was higher than data from Taccone 
et al.11, in which 70% of the patients reached 
amikacin peak levels above 64 µg/mL.
Seven patients have complete data of Cmax 
as well as the MIC data from the isolates of these 
patients’ specimen. Among these 7 patients, 4 
patients (57%) had Cmax/MIC ratio above 8 
or reached optimal amikacin concentration. It 
was not far from Duzynska et al.16 who reported 
63% (40/63) patients with sepsis reached Cmax/
MIC ratio >8. In the future, studies with larger 
samples should be done in Indonesia.
In this study, all patients received amikacin 
1 g, in accordance of local guidance. Taking into 
accounts patient’s individual body weight, the 
dose range was 18.5 + 4.1 mg/kgBW. This was 
different from Najmeddin et al.17, who found 
mean dose of 22.4 (SD 0.4) mg/kgBW was given 
to septic patients in their study. Taccone et al.11 
Table 3. Patients with optimal amikacin level (Cmax/MIC ratio >8), according to Cmax and MIC data
Patient No. Cmax (µg/mL) Bacteria MIC (µg/mL) Cmax/MIC Ratio Optimal
4 103.31 K. pneumonia 2 51.66 Yes
5 91.78 K. pneumonia 1.5 61.19 Yes 
11 143.46 A. baumanii 256 0.56 No
13 128.2 A. baumanii 256 0.50 No
16 45.87 K. pneumoniae 3 15.29 Yes
P. aeruginosa 2 22.94 Yes  
18 147.93 K. pneumoniae 3 49.31 Yes
P. aeruginosa 32 4.62 No 
19 69.56 A. baumanii 0.75 92.75 Yes 
Total 7 patients 9 bacteria
Table 4. Numbers of patients achieving therapeutic level 
of amikasin related to dose
Regimen Peak >64µg/mL, n (%)
Peak <64 µg/
mL, n (%)
<25 mg/kgBW 17 (74) 3 (13)
25 mg/kgBW 2 (9) 0 (0)
>25 mg/kgBW 1 (4) 0 (0)
Minimum Inhibitory Concentration (MIC) 
K. pneumoniae, A. baumanii, P. aeruginosa 
and E. coli were the most common gram-negative 
bacteria found in the microbial culture from 
patients in ICU RSCM from May-August 2015. 
Data of MIC can be seen at Table 5. Seventy two 
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found that only 9% of all patients with 15 mg/
kgBW dose reached the peak levels of >64 µg/
mL, while 72% reached the peak levels with 25 
mg/kgBW dose.
Duzynska et al.16 concluded that patients in 
septic condition need loading dose of amikacin 
more than 25 mg/kgBW to reach its optimal 
levels. Similar results was found by Mahmoudi 
et al.7, amikacin dose of more than 25 mg/kgBW 
was needed to reach the optimal levels in patients 
with increased volume distribution (Vd). This 
study found that with the mean dose of 18.5 
(SD 4.1) mg/kgBW, the peak levels of >64 µg/
mL could be reached in 87% patients. Most 
(18/23) patients got amikacin dose of 15-25 mg/
kgBW. This difference can be associated with the 
relatively small Vd in our subjects, which can 
also be caused by dehydration.
Peak concentrations of amikacin in our 
samples were quite high and had wide range 
(median 86.4 [43.5-238] µg/mL). Dose and 
volume distribution could influence this 
Table 5. M IC data of Gram-negative isolates from stock bacteria of FMUI-RSCM (N=72 isolates)
No. Isolate MIC K. pneumoniae (µg/mL)
MIC A. baumanii  
(µg/mL)
MIC P. aeruginosa 
(µg/mL) MIC E. coli (µg/mL)
1. 0.75 0.75 1.5 0.75
2. 0.75 0.75 2 1
3. 0.75 1 2 1
4. 0.75 1.5 3 1.5
5. 0.75 2 3 4
6. 0.75 2 16 16
7. 0.75 2 16
8. 1 2 32
9. 1 3 32
10. 1 3 32
11. 1 3 48
12. 1.5 3 >256
13. 1.5 48 >256
14. 1.5 >256 >256


















 Total isolates (N) 32 19 15 6
Stock of bacteria were isolated from ICU patients in period May-August 2015
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condition.18 All subjects in this study received 
1 g amikacin, not based on patient body weight. 
Another factor was volume distribution. Volume 
distribution is influenced by plasma binding 
protein, hydration, fever, sepsis, burn lesion, lean 
body mass, etc.19 Sepsis can cause fluctuation of 
volume distribution.20 Lugo et al.21 found that 
the hemodynamic and vital support influenced 
the kinetics of amikacin in their patients. 
Three major factors which have impact on 
volume distribution were body weight, oxygen 
extraction, and serum albumin. The impact of 
albumin to amikacin could be neglected because 
of the insignificant amikacin protein binding.22 
Effect of dehydration could not be excluded due 
to limited data. Influence of body weight could 
be minimized by body weight dosing regimen. 
However, the simultaneous analysis of 
therapeutic levels and peak levels of amikacin 
in our study could only be performed in 7 
subjects which was the limitation of the study. 
The optimal levels illustrates interaction 
between the drug levels in a patient (host) with 
the sensitivity of the organism (agent). The 
amikacin therapeutic levels in ICU is described 
as the amikacin blood levels that is regarded as 
sufficient to kill most of the bacteries that are 
commonly present in ICU, based on bacterial 
MIC data in a certain period. The therapeutic 
levels do not take into account the bacterial 
sensitivity of each patient.
Our study shows that 3 of 7 subjects had 
amikacin levels above 64 µg/mL but the Cmax/C 
ratio were below 8 (i.e. not optimal to kill the 
pathogens). From this data we can conclude 
that the consideration of amikacin dose cannot 
be done simply by using therapeutic levels, but 
also have to take account for the optimal levels. 
Therapeutic drug monitoring of an antibiotics 
must consider the optimal levels of each 
antibiotic for each individual patient, beside the 
drug plasma levels. There was one patient with 
drug plasma levels less than 64 µg/mL, with 
Cmax/MIC ratio >8. This finding might show 
the importance of analyzing drug requirement 
for each patients. Therefore, measurement 
of amikacin optimal levels should be done 
whenever a definite therapy is given.
In this study, four major Gram negative 
bacteria i.e. K. pneumoniae, A. baumanii, 
P. aeruginosa and E. coli were found. Lee 
et al.23 reported that infection caused by 
Enterobactericeae (K. pneumoniae and E. coli) 
were increased during their study period (from 
2003 to 2011) in Taiwan. Lee also found the 
increase of resistance levels of A. baumanii. 
This data was similar with our finding, in which 
A. baumanii had the highest resistance levels 
among other Gram negative bacterias.
An interesting finding in MIC is shown in 
Table 5. The MICs of K.pneumonia, A. baumanii 
and P. aeruginosa were not distributed normally. 
Some bacteria had low and, contrastingly, some 
of them had high MICs. This phenomenon could 
be caused by plasmid transfer from a resistant 
bacteria. An in vitro study by Vaidya24 found a 
horizontal resistant transfer by conjugation from 
Enterobactericeae strain Extended Spectrum 
β-Lactamase (ESBL) against many antibiotics 
include amikacin. The same condition could 
occur naturally in hospital setting.
Susceptibility rate of some pathogens were 
still quite high for E. coli and K. pneumonia 
but were decreasing for A. baumanii (63%) and 
P. aeruginosa (47%). This finding was similar 
with data from Kizirgilet al.25, which showed 
that the susceptibility rate of K. pneumoniae 
and E. coli strain ESBL were 83.3% and 94.5%, 
respectively.
Only 7 patients had complete data set for 
calculation of Cmax/MIC ratio. It was caused 
by our limited access to the specimen for 
susceptibility test. The calculation of Cmax/
MIC ratio were performed only in a few patients. 
If we used MIC 8 µg/mL as a consideration to 
calculate target peak levels, the data would not 
represent real condition in our ICU.
Another limitation was patient recruitment. 
Amikacin was used as second line empirical 
therapy in this study site hospital. Some patients 
received amikacin after treatment failure with 
carbapenem or cephalosporin. Most of the septic 
patients had renal impairment, so they were 
excluded from this study.
Result of this study could be used for 
revising patient management in the hospital. 
Drug use study could improve patient safety 
and optimizing the benefit of antibiotic therapy. 
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Similar evaluation of other antibiotics should be 
done, espesially in critically ill patients. 
CONCLUSION
By giving 1 g of amikacin, only 57% of 
patients with sepsis reached an optimal Cmax/
MIC ratio of 8 or more, although most of the 
patients reached peak levels of >64 µg/mL. 
For optimal septic therapy, the evaluation of 
Cmax and MIC were needed. Optimalization 
of amikacin therapy could be achieved by 
monitoring plasma concentration because of 
its wide interindividual variability. Amikacin 
regimen based on body weight could be 
considered to minimize this variability.
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